Current Oncology Reports

, 16:408 | Cite as

Gestational Trophoblastic Tumours: An Update for 2014

  • Fieke E. M. Froeling
  • Michael J. SecklEmail author
Gynecologic Cancers (NS Reed, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers


Gestational trophoblastic disease describes a variety of pregnancy-related diseases including the premalignant conditions of a partial and complete hydatidiform mole and the malignant disorders of invasive mole, choriocarcinoma and the rare placental-site trophoblastic tumour and epithelioid trophoblastic tumour. The availability of a highly sensitive tumour marker in the form of human chorionic gonadotrophin, the chemosensitive character of the disease with effective treatment strategies and centralization of care of a rare group of diseases has resulted in excellent survival rates, which can exceed 98 %. This review gives a general overview of gestational trophoblastic disease, the most recent insights in aetiology and pathology and a summary of the different management strategies.


Gestational trophoblastic disease Molar pregnancy Choriocarcinoma Trophoblastic tumours Pregnancy-related diseases Gynaecological cancers Oncology Choriocarcinoma Trophoblastic tumours Pregnancy-related diseases Gynaecologic cancers 


Compliance with Ethics Guidelines

Conflict of Interest

Fieke E. M. Froeling and Michael J. Seckl declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med. 1994;39:155–62.PubMedGoogle Scholar
  3. 3.
    Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. BJOG. 2002;109(1):99–102.PubMedCrossRefGoogle Scholar
  4. 4.
    Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol. 2007;19(5):486–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Fisher RA, Lawler SD, Povey S, Bagshawe KD. Genetically homozygous choriocarcinoma following pregnancy with hydatidiform mole. Br J Cancer. 1988;58:788–892.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Seckl MJ, Fisher RA, Salerno GA, Rees H, Paradinas FJ, Foskett M, et al. Choriocarcinoma and partial hydatidiform moles. Lancet. 2000;356:36–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet. 2009;374(9683):48–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Fisher RA, Lavery SA, Carby A, Abu-Hayyeh S, Swingler R, Sebire NJ, et al. What a difference an egg makes. Lancet. 2011;378(9807):1974.PubMedCrossRefGoogle Scholar
  9. 9.
    Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, Kuick R, et al. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat Genet. 2006;38(3):300–2.PubMedCrossRefGoogle Scholar
  10. 10.••
    Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, et al. Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi39–50. This is a recently published European Society for Medical Oncology guideline which gives a clear general overview of GTD.PubMedCrossRefGoogle Scholar
  11. 11.
    Arima T, Imamura T, Amada S, Tsuneyoshi M, Wake N. Genetic origin of malignant trophoblastic neoplasms. Cancer Genet Cytogenet. 1994;73:95–102.PubMedCrossRefGoogle Scholar
  12. 12.
    Osada H, Kawata M, Yamada M, Okumura K, Takamizawa H. Genetic identification of pregnancies responsible for choriocarcinomas after multiple pregnancies by restriction fragment length polymorphism analysis. Am J Obstet Gynaecol. 1991;165:682–8.CrossRefGoogle Scholar
  13. 13.
    Fisher RA, Savage PM, MacDermott C, Hook J, Sebire NJ, Lindsay I, et al. The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies. Gynecol Oncol. 2007;107(3):413–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Petts G, Fisher RA, Short D, Lindsay I, Seckl MJ, Sebire NJ. Histopathological and immunohistochemical features of early hydatidiform mole in relation to subsequent development of persistent gestational trophoblastic disease. J Reprod Med. 2014;59(5–6):213–20.PubMedGoogle Scholar
  15. 15.
    Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol. 1998;22(11):1393–403.PubMedCrossRefGoogle Scholar
  16. 16.
    Hou JL, Wan XR, Xiang Y, Qi QW, Yang XY. Changes of clinical features in hydatidiform mole: analysis of 113 cases. J Reprod Med. 2008;53(8):629–33.PubMedGoogle Scholar
  17. 17.
    Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Histomorphometric features of hydatidiform moles in early pregnancy: relationship to detectability by ultrasound examination. Ultrasound Obstet Gynecol. 2007;29(1):76–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Johns J, Greenwold N, Buckley S, Jauniaux E. A prospective study of ultrasound screening for molar pregnancies in missed miscarriages. Ultrasound Obstet Gynecol. 2005;25(5):493–7.PubMedCrossRefGoogle Scholar
  19. 19.
    National Institute for Health and Care Excellence (NICE). Ectopic pregnancy and miscarriage: Diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. Available from:
  20. 20.
    Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, Francis RJ, Short D, et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet. 2002;359:2165–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Bagshawe KD, Dent J, Webb J. Hydatidiform mole in the United Kingdom 1973–1983. Lancet. 1986;ii:673.CrossRefGoogle Scholar
  22. 22.
    Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med. 2006;51(10):764–6.PubMedGoogle Scholar
  23. 23.
    Sebire NJ, Foskett M, Short D, Savage P, Stewart W, Thomson M, et al. Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit. BJOG. 2007;114(6):760–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A Prog Rep J Reprod Med. 2002;47(6):445–50.Google Scholar
  25. 25.••
    Agarwal R, Teoh S, Short D, Harvey R, Savage PM, Seckl MJ. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet. 2012;379(9811):130–5. This is retrospective study of 76 women with persistently elevated hCG levels more than 6 months after evacuation showed that continued observation is safe as long as the hCG level is decreasing, resulting in a change in the widely accepted criteria to initiate treatment.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet. 2002;77(3):285–7.CrossRefGoogle Scholar
  27. 27.
    Agarwal R, Harding V, Short D, Fisher RA, Sebire NJ, Harvey R, et al. Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia. Br J Cancer. 2012;106(6):1089–94.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Alazzam M, Tidy J, Hancock BW, Osborne R, Lawrie TA. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012;7, CD007102.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Lurain JR, Chapman-Davis E, Hoekstra AV, Schink JC. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57(7–8):283–7.PubMedGoogle Scholar
  30. 30.
    McNeish IA, Strickland S, Holden L, Rustin GJS, Foskett M, Seckl MJ, et al. Low risk persistent gestational trophoblastic disease: outcome following initial treatment with low-dose methotrexate and folinic acid, 1992–2000. J Clin Oncol. 2002;20(7):1838–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Sita-Lumsden A, Short D, Lindsay I, Sebire NJ, Adjogatse D, Seckl MJ, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009. Br J Cancer. 2012;107(11):1810–4.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.•
    Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125(3):576–9. This is a retrospective study that showed a reduced relapse rate with three consolidation cycles compared with two cycles of methotrexate for treatment of low-risk GTN. On the basis of this study and extensive experience in the UK, treatment with three consolidation cycles is recommended for low-risk disease.PubMedCrossRefGoogle Scholar
  33. 33.
    Deng L, Zhang J, Wu T, Lawrie TA. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev. 2013;1, CD005196.PubMedGoogle Scholar
  34. 34.•
    Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31(2):280–6. This retrospective analysis of 438 patients who received EMA/CO for treatment of high-risk GTN demonstrated a clear benefit of starting treatment with low-dose EP in patients with a large disease burden. Induction therapy with low-dose EP should therefore routinely be considered in the treatment of very high-risk GTN.PubMedCrossRefGoogle Scholar
  35. 35.
    Agarwal R, Alifrangis C, Everard J, Savage PM, Short D, Tidy J, et al. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995–2010. J Reprod Med. 2014;59(1–2):7–12.PubMedGoogle Scholar
  36. 36.
    Powles T, Young A, Sammit A, Stebbing J, Short D, Bower M, et al. The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. Br J Cancer. 2006;95(9):1145–7.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Newlands ES, Holden L, Seckl MJ, McNeish I, Strickland S, Rustin GJ. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med. 2002;47(6):465–71.PubMedGoogle Scholar
  38. 38.
    Seckl MJ, Newlands ES. Investigation and treatment of patients with persistent gestational trophoblastic disease and gestational trophoblastic tumours/neoplasia in the United Kingdom. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA, editors. Gestational trophoblastic disease. 3rd ed. 2009. p. 335–65.
  39. 39.
    Ahamed E, Short D, North B, Savage PM, Seckl MJ. Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving? J Reprod Med. 2012;57(5–6):262–9.PubMedGoogle Scholar
  40. 40.
    Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 2007;96(5):732–7.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Dhillon T, Palmieri C, Sebire NJ, Lindsay I, Newlands ES, Schmid P, et al. Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med. 2006;51(11):879–87.PubMedGoogle Scholar
  42. 42.
    El-Helw LM, Seckl MJ, Haynes R, Evans LS, Lorigan PC, Long J, et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. Br J Cancer. 2005;93(6):620–1.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    The ISSTD Global Placental Site Trophoblastic Tumour Database. International Society of the Study of Trophoblastic Diseases.
  44. 44.
    Williams J, Short D, Dayal L, Strickland S, Harvey R, Tin T, et al. Effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia. J Reprod Med. 2014;59(5–6):248–54.PubMedGoogle Scholar
  45. 45.
    Blagden SP, Foskett MA, Fisher RA, Short D, Fuller S, Newlands ES, et al. The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer. 2002;86:26–30.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Bower M, Rustin GJS, Newlands ES, Holden L, Short D, Foskett M, et al. Chemotherapy for gestational trophoblastic tumours hastens menapause by 3 years. Eur J Cancer. 1998;34:1204–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Woolas RP, Bower M, Newlands ES, Seckl MJ, Short D, Holden L. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynaecol. 1998;105:1032–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Rustin GJS, Booth M, Dent J, Salt S, Rustin F, Bagshawe KD. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J. 1984;288:103–6.CrossRefGoogle Scholar
  49. 49.
    Rustin GJS, Newlands ES, Lutz J-M, Holden L, Bagshawe KD, Hiscox JG, et al. Combination but not single agent methotrexate chemotherapy for gestational trophoblastic tumours (GTT) increases the incidence of second tumours. J Clin Oncol. 1996;14:2769–73.PubMedGoogle Scholar
  50. 50.
    Savage PM, Cooke R, O’Nions J, Krell J, Kwan A, Michelle C, et al. The effects of single agent and combination chemotherapy for gestational trophoblastic tumours on risks of second malignancy and early menopause. J Clin Oncol. 2014; in press.Google Scholar
  51. 51.•
    Kohorn EI. Worldwide survey of the results of treating gestational trophoblastic disease. J Reprod Med. 2014;59(3–4):145–53. This is a worldwide survey including 17 countries showing the importance of centralized patient care, which gives better results and improved survival.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Medical Oncology, Charing Cross Gestational Trophoblastic Disease CentreImperial College Healthcare NHS Trust and Imperial College LondonLondonUK

Personalised recommendations